HUP1300509A2 - CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra - Google Patents
CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásraInfo
- Publication number
- HUP1300509A2 HUP1300509A2 HU1300509A HUP1300509A HUP1300509A2 HU P1300509 A2 HUP1300509 A2 HU P1300509A2 HU 1300509 A HU1300509 A HU 1300509A HU P1300509 A HUP1300509 A HU P1300509A HU P1300509 A2 HUP1300509 A2 HU P1300509A2
- Authority
- HU
- Hungary
- Prior art keywords
- igfbp2
- cxcl12
- chemokine
- motif
- insulin
- Prior art date
Links
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 title 2
- 102000006573 Chemokine CXCL12 Human genes 0.000 title 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 title 1
- 101100508040 Danio rerio igfbp2a gene Proteins 0.000 title 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 101150071737 igfbp2 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 201000002528 pancreatic cancer Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1300509A HUP1300509A2 (hu) | 2013-08-30 | 2013-08-30 | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra |
AU2014313964A AU2014313964A1 (en) | 2013-08-30 | 2014-08-27 | CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
EP14802110.8A EP3039035A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
US14/915,590 US20160215053A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
JP2016537390A JP2016529278A (ja) | 2013-08-30 | 2014-08-27 | 真性糖尿病に併発する膵臓癌の治療に適用されるcxcl12(ケモカイン(c−x−cモチーフ)リガンド12)及びigfbp2インヒビター |
PCT/HU2014/000077 WO2015028831A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
CA2922595A CA2922595A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1300509A HUP1300509A2 (hu) | 2013-08-30 | 2013-08-30 | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP1300509A2 true HUP1300509A2 (hu) | 2015-03-30 |
Family
ID=89991239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU1300509A HUP1300509A2 (hu) | 2013-08-30 | 2013-08-30 | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160215053A1 (hu) |
EP (1) | EP3039035A1 (hu) |
JP (1) | JP2016529278A (hu) |
AU (1) | AU2014313964A1 (hu) |
CA (1) | CA2922595A1 (hu) |
HU (1) | HUP1300509A2 (hu) |
WO (1) | WO2015028831A1 (hu) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115128283A (zh) * | 2022-07-20 | 2022-09-30 | 郑州大学第一附属医院 | 一种重症急性胰腺炎疾病的标志物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773419A (en) * | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
EP2308996A1 (en) * | 1998-03-30 | 2011-04-13 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis |
EP2247302B1 (en) * | 2008-02-27 | 2015-08-26 | The Medical College of Wisconsin, Inc. | An engineered cxcl12 alpha locked dimer polypeptide |
EP3301176B1 (en) * | 2011-02-11 | 2019-09-25 | The Rockefeller University | Method for identifying nucleic acids regulating metastasation |
-
2013
- 2013-08-30 HU HU1300509A patent/HUP1300509A2/hu not_active IP Right Cessation
-
2014
- 2014-08-27 JP JP2016537390A patent/JP2016529278A/ja active Pending
- 2014-08-27 US US14/915,590 patent/US20160215053A1/en not_active Abandoned
- 2014-08-27 CA CA2922595A patent/CA2922595A1/en not_active Abandoned
- 2014-08-27 WO PCT/HU2014/000077 patent/WO2015028831A1/en active Application Filing
- 2014-08-27 AU AU2014313964A patent/AU2014313964A1/en not_active Abandoned
- 2014-08-27 EP EP14802110.8A patent/EP3039035A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2015028831A9 (en) | 2015-04-23 |
US20160215053A1 (en) | 2016-07-28 |
EP3039035A1 (en) | 2016-07-06 |
CA2922595A1 (en) | 2015-03-05 |
AU2014313964A1 (en) | 2016-03-17 |
WO2015028831A1 (en) | 2015-03-05 |
JP2016529278A (ja) | 2016-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267609B (en) | Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases | |
IL274151A (en) | Trispecific binding proteins and methods of use | |
HK1245287A1 (zh) | IL13RAα2結合劑和其在癌症治療中的用途 | |
HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
HK1215540A1 (zh) | 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑 | |
HK1221178A1 (zh) | 卡博替尼劑型及其在癌症治療中的使用 | |
IL259547B (en) | Isolated protein and preparations containing it for use in the treatment of disorders caused by il-1 | |
HK1208629A1 (en) | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency hgh-xten | |
IL269710A (en) | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in cancer therapy | |
HUE057257T2 (hu) | Folyékony készítmény gyomor- és nyelõcsõ reflux kezelésében történõ alkalmazásra | |
IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
HK1248589A1 (zh) | 檸檬酸鐵在治療缺鐵性貧血中的用途 | |
EP3708173C0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING MIRNA-3140 FOR THE TREATMENT OF CANCER | |
SG11202111476RA (en) | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer | |
HUP1300509A2 (hu) | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra | |
HK1207289A1 (en) | Composition for prevention of vasoactivity in the treatment of blood loss and anemia | |
HK1184699A1 (zh) | 結合性核酸及其在癌症治療中的用途 | |
EP3648789C0 (en) | MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY | |
EP3085710A4 (en) | Protein and use thereof in treating multiple sclerosis | |
EP2941248A4 (en) | COMPOSITION AND METHOD FOR TREATING BODY SURFACE | |
SG11201506963UA (en) | Kits and methods for the treatment of cancer using gliadin peptides | |
IL277112A (en) | Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer | |
EP2833901A4 (en) | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF METANEUMOVIRUS INFECTION (MPV) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees | ||
RH9A | Decision on the lapse of patent protection withdrawn | ||
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |